Literature DB >> 15549090

Targeted cancer therapy.

Charles Sawyers1.   

Abstract

Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Complex networks of regulatory factors, the tumour microenvironment and stress signals, such as those resulting from damaged DNA, dictate whether cancer cells proliferate or die. Recent progress in understanding the molecular changes that underlie cancer development offer the prospect of specifically targeting malfunctioning molecules and pathways to achieve more effective and rational cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15549090     DOI: 10.1038/nature03095

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  332 in total

Review 1.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.

Authors:  Inna V Fedorenko; Kim H T Paraiso; Keiran S M Smalley
Journal:  Biochem Pharmacol       Date:  2011-05-25       Impact factor: 5.858

2.  PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.

Authors:  Iris Eke; Ulrike Koch; Stephanie Hehlgans; Veit Sandfort; Fabio Stanchi; Daniel Zips; Michael Baumann; Anna Shevchenko; Christian Pilarsky; Michael Haase; Gustavo B Baretton; Véronique Calleja; Banafshé Larijani; Reinhard Fässler; Nils Cordes
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 3.  Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Authors:  Qi-Wen Fan; William A Weiss
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 4.  A brief history of melanoma: from mummies to mutations.

Authors:  Vito W Rebecca; Vernon K Sondak; Keiran S M Smalley
Journal:  Melanoma Res       Date:  2012-04       Impact factor: 3.599

5.  Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.

Authors:  Tiannan Guo; Yi Zhu; Chee Sian Gan; Sze Sing Lee; Jiang Zhu; Haixia Wang; Xin Li; James Christensen; Shiang Huang; Oi Lian Kon; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-08-16       Impact factor: 5.911

6.  Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome.

Authors:  Tiannan Guo; Sze Sing Lee; Wai Har Ng; Yi Zhu; Chee Sian Gan; Jiang Zhu; Haixia Wang; Shiang Huang; Siu Kwan Sze; Oi Lian Kon
Journal:  Cell Mol Life Sci       Date:  2010-10-16       Impact factor: 9.261

7.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 8.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

9.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Authors:  Hans-Guido Wendel; Elisa de Stanchina; Enriqué Cepero; Sagarika Ray; Michael Emig; Jordan S Fridman; Darren R Veach; William G Bornmann; Bayard Clarkson; W Richard McCombie; Scott C Kogan; Andreas Hochhaus; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

10.  Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.

Authors:  Ting Chen; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Pengyuan Sun; Jinyong Peng; Zhihao Liu; Xiaobo Yang; Kexin Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.